Ratings Walgreens Boots Alliance, Inc.

Equities

WBA

US9314271084

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
20.69 USD -0.62% Intraday chart for Walgreens Boots Alliance, Inc. -3.95% -20.76%

Summary

  • The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

  • The company's attractive earnings multiples are brought to light by a P/E ratio at 12.75 for the current year.
  • The stock, which is currently worth 2024 to 0.18 times its sales, is clearly overvalued in comparison with peers.
  • The company appears to be poorly valued given its net asset value.
  • The company has a low valuation given the cash flows generated by its activity.
  • The company is one of the best yield companies with high dividend expectations.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Drug Retailers

Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes